Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice

Cancer Treatment Reviews

Volumn 43, Issue , 2016, Pages 113-123

  Lalami, Y ^a   Awada, A ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Head and neck cancer; HPV; Immune system; Immunotherapy; Tumor immune infiltration

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB;

CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER RADIOTHERAPY; CD4 CD8 RATIO; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL THERAPY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE SYSTEM; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; CARCINOGENESIS; DISEASE MANAGEMENT; DRUG EFFECTS; FORECASTING; GENOMIC INSTABILITY; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; PROCEDURES; TRANSLATIONAL RESEARCH; TRENDS;

CARCINOGENESIS; DISEASE MANAGEMENT; FORECASTING; GENOMIC INSTABILITY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; TRANSLATIONAL MEDICAL RESEARCH; TUMOR ESCAPE;

EID: 84961999214     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.01.001     Document Type: Review

References (196)

1. Argiris A., Karamouzis M.V., Raben D., Ferris R.L. Head and neck cancer. Lancet 2008, 371:1695-1709.
2. Torre L.A., Bray F., Siegel R.L., Ferlay J., et al. Global cancer statistics 2012. CA Cancer J Clin 2015, 65(2):87-108.
3. SEER cancer statistics review, 1975-2008 2011, National Cancer Institute, Bethesda, MD. N.N.A. Howlader, M. Krapcho, N. Neyman (Eds.).
4. Vokes E.E., Weichselbaum R.R., Lippman S.M., Hong W.K. Head and neck cancer. N Engl J Med 1993, 328:184-194.
5. Haddad R.I., Shin D.M. Recent advances in head and neck cancer. N Engl J Med 2008, 359:1143-1154.
6. Colevas A.D. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006, 24:2644-2652.
7. Forastiere A.A., Metch B., Schuller D.E., et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992, 10:1245-1251.
8. Guardiola E., Peyrade F., Chaigneau L., et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004, 40:2071-2076.
9. Specenier P., Vermorken J.B. The role of taxanes and targeted therapies in locally advanced head and neck cancer. Curr Opin Oncol 2007, 195-201.
10. Vermorken J.B., Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 2010, 21(Suppl. 7):vii252-vii261.
11. Leon X., Hitt R., Constenla M., et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005, 17:418-424.
12. Vermorken J.B., Mesia R., Rivera F., et al. Platinum based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359:1116-1127.
13. Ferris R.L., Jaffee E.M., Ferrone S. Tumor antigen-targeted, monoclonal antibody based immunotherapy: clinical response, cellular immunity, and immune-escape. J Clin Oncol 2010, 28:4390-4399.
14. Lee S.C., Srivastava R.M., Lopez-Albaitero A., Ferrone S., Ferris R.L. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res 2011, 50:248-254.
15. Schmitz S., Ang K.K., Vermorken J.B., et al. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future direction. Cancer Treat Rev 2014 Apr, 40(3):390-404.
16. Stewart J.S., Cohen E.E., Licitra L., et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009, 27:1864-1871.
17. Machiels J.P., Subramanian S., Ruzsa A., et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 2011 Apr, 12(4):333-343.
18. Argiris A., Ghebremichael M., Gilbert J., et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 2013 Apr 10, 31(11):1405-1414.
19. Cupisol D., Seiwert T.Y., Fayette J. A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of stage 2 (S2) following crossover. J Clin Oncol 2013, (suppl; abstr 6001).
20. Machiels J.P., Haddad R.I., Fayette J., et al. Afatinib versus methotrexate (MTX) as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy: primary efficacy results of LUX-Head & Neck 1, a phase III trial. Ann Oncol 2014, 25(5):1.
21. Ang K.K., Harris J., Wheeler R., Weber R., Rosenthal D.I., Nguyen-Tan P.F., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363(1):24-35.
22. Rischin D., Young R.J., Fisher R., Fox S.B., Le Q.T., Peters L.J., et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010, 28(27):4142-4148.
23. Gillison M.L., D'Souza G., Westra W., Sugar E., Xiao W., Begum S., et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008, 100(6):407-420.
24. Adelstein D.J., Ridge J.A., Gillison M.L., et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, DC. Head Neck 2009, 31:1393-1422.
25. Chaturvedi A.K., Engels E.A., Pfeiffer R.M., Hernandez B.Y., Xiao W., Kim E., et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011, 29(32):4294-4301.
26. Chaturvedi A.K., Engels E.A., Anderson W.F., Gillison M.L. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008, 26:612-619.
27. Licitra L., Perrone F., Bossi P., et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006, 24(36):5630-5636.
28. Fakhry C., Westra W.H., Li S., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008, 100(4):261-269.
29. Worden F.P., Kumar B., Lee J.S. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008, 26(19):3138-3146.
30. Dayyani F., Etzel C.J., Liu M., Ho C.H., Lippman S.M., Tsao A.S. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010.
31. Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu L., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000, 92:709-720.
32. Duray A., Descamps G., Arafa M., Decaestecker C., Remmelink M., Sirtaine N., et al. High incidence of high-risk HPV in benign and malignant lesions of the larynx. Int J Oncol 2011, 39:51-59.
33. Koskinen W.J., Chen R.W., Leivo I., Mäkitie A., Bäck L., Kontio R., et al. Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int J Cancer 2003, 107:401-406.
34. Ragin C.C., Modugno F., Gollin S.M. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 2007, 86:104-114.
35. Morshed K. Association between human papillomavirus infection and laryngeal squamous cell carcinoma. J Med Virol 2010, 82:1017-1023.
36. Rosenquist K., Wennerberg J., Annertz K., Schildt E.B., Hansson B.G., Bladström A., et al. Recurrence in patients with oral and oropharyngeal squamous cell carcinoma: Humanpapillomavirus and other risk factors. Acta Otolaryngol 2007, 127:980-987.
37. Clayman G.L., Stewart M.G., Weber R.S., el-Naggar A.K., Grimm E.A. Human papillomavirus in laryngeal and hypopharyngeal carcinomas. Relationship to survival. Arch Otolaryngol Head Neck Surg 1994, 120:743-748.
38. Duray A., Descamps G., Decaestecker C., Remmelink M., Sirtaine N., Lechien J., et al. Human papillomavirus DNA strongly correlates with a poorer prognosis in oral cavity carcinoma. Laryngoscope 2012, 122:1558-1565.
39. Psyrri A., Boutati E., Karageorgopoulou S. Human papillomavirus in head and neck cancers: biology, prognosis, hope of treatment, and vaccines. Anti-Cancer Drugs Aug 2011, 22(7):586-590.
40. Gildener-Leapman N., Ferris R.L., Bauman J.E. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol 2013, 49:1089-1096.
41. Hong A.M., Dobbins T.A., Lee C.S., Jones D., Harnett G.B., Armstrong B.K., et al. Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer 2010, 103:1510-1517.
42. Masterson L., Moualed D., Liu Z.W., et al. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur J Cancer 2014, 50(15):2636-2648.
43. Vigneron N., Stroobant V., Vanden Eynde B.J., et al. Database of Tcell-defined human tumor antigens: the 2013 update. Cancer Immun 2013, 2013(13):15.
44. Vesely M.D., Kershaw M.H., Schreiber R.D. Natural innate and adaptive immunity to cancer. Ann Rev Immunol 2011, 29:235-271.
45. Allen C.T., Judd N.P., Bui J.D., Uppaluri R. The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope 2012, 122(1):144-157.
46. Mittal D., Gubin M.M., Schreiber R.D., et al. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014, 27C:16-25.
47. Buckowitz A., Knaebel H.P., Benner A., et al. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequencyofdistantmetastases. Br J Cancer 2005, 92:1746-1753.
48. Ji R.-R., Chasalow S.D., Wang L., et al. An immune-active tumor micro- environment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012, 61:1019-1031.
49. Denkert C., Loibl S., Noske A. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010, 28(1):105-113.
50. Deschoolmeester V., Baay M., Van Marck E., et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol 2010 Apr, 12(11):19.
51. Uppaluri R., Dunn G.P., Lewis J.S. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun 2008, 8:16.
52. Gooden M.J., de Bock G.H., Leffers N., et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011, 105(1):93-103.
53. Wolf G.T., Chepeha D.B., Bellile E., et al. Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study. Oral Oncol 2015 Jan, 51(1):90-95.
54. Distel L.V., Fickenscher R., Dietel K., et al. Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease. Oral Oncol 2009, 45(10):167-174.
55. Wolf G.T., Hudson J.L., Peterson K.A., et al. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg 1986, 95:142-152.
56. Badoual C., Hans S., Rodriguez J., et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006, 12:465-472.
57. Marcus B., Arenberg D., Lee J., et al. Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer 2004, 101:2779-2787.
58. Sun D.S., Zhao M.Q., Xia M., et al. The correlation between tumor-infiltrating Foxp3+ regulatory T cells and cyclooxygenase-2 expression and their association with recurrence in resected head and neck cancers. Med Oncol 2012, 29:707-713.
59. Roncador G., Brown P.J., Maestre L., et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005, 35(6):1681-1691.
60. Sun W., Li W.J., Wu C.Y. CD45RA-Foxp3high but not CD45RA+Foxp3low suppressive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous cell carcinoma and correlated with tumor progression. J Exp Clin Cancer Res 2014, 25:33.
61. Ladoire S., Martin F., Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011, 60(7):909-918.
62. Wansom D., Light E., Thomas D., et al. Infiltrating lymphocytes and human papillomavirus-16-associated oropharyngeal cancer. Laryngoscope 2012, 122:121-127.
63. Albers A., Abe K., Hunt J., et al. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 2005, 65(23):1146-1155.
64. Wansom D., Light E., Worden F., et al. Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 2010, 136(12):1267-1273.
65. Russell S., Angell T., Lechner M., et al. Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma. Head Neck Oncol. 2013, 5(3):24.
66. Nasman, Romanitan M., Nordfors C., et al. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PloS ONE 2012, 7.
67. Jung A.C., Guihard S., Krugell S., Ledrappier S., Brochot A., Dalstein V., et al. CD8-alpha T-cell infiltration in human papillomavirus-related oropharyngeal carcinoma correlates with improved patient prognosis. Int J Cancer 2013, 132:26-36.
68. Lukesova E., Boucek J., Rotnaglova E., et al. High level of tregs is a positive prognostic marker in patients with HPV-positive oral and oropharyngeal squamous cell carcinomas. BioMed Res Int 2014, 2014:1-11.
69. Nordfors C., Grün N., Tertipis N., et al. CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. Eur J Cancer 2013 Jul, 49(11):2522-2530.
70. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646.
71. Duray A., Demoulin S., Hubert P., Delvenne P., Saussez S. Immune suppression in head and neck cancers: a review. Clin Dev Immunol 2010, 2010:701657. 10.1155/2010/701657.
72. Meissner M., Reichert T.E., Kunkel M., Gooding W., Whiteside T.L., Ferrone S., et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 2005, 11(7):2552-2560.
73. Young M.R. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck 2006, 28(5):462-470.
74. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006, 6(4):295-307.
75. Ladanyi A., Somlai B., Gilde K., et al. T-cell activation marker expression on tumor infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 2004, 10(2):521-530.
76. Raghavan S., Quiding-Jadierbrink M. Regulatory T cells in gastrointestinal tumors. Expert Rev Gastroenterol Hepatol 2011, 5(4):489-501.
77. Ke X., Wang J., Li J., et al. Roles of CD4+CD25high FOXP3+ Tregs in lymphomas and tumors are complex. Front Biosci 2008, 13(10):3986-4001.
78. Alvaro T., Lejeune M., Salvado M.T., et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005, 11(4):1467-1473.
79. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
80. Lopez-Albaitero A., Nayak J.V., Ogino T., et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006, 176:3402-3409.
81. Ferris R.L., Hunt J.L., Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res 2005, 33:113-133.
82. Albaitero A., Nayak J.V., Ogino T., et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006, 176:3402.
83. Wollenberg B., Zeidler R., Lebeau A., Mack B., Lang S. Lack of B7.1 and B7.2 on head and neck cancer cells and possible significance for gene therapy. Int J Mol Med 1998 Aug, 2(2):167-171.
84. Silva T.G., Crispim J.C., Miranda F.A., Hassumi M.K., de Mello J.M., Simões R.T., et al. Expression of the nonclassical HLA-G and HLA-E molecules in laryngeal lesions as biomarkers of tumor invasiveness. Histol Histopathol 2011 Dec, 26(12):1487-1497.
85. Kuss I., Hathaway B., Ferris R.L., Gooding W., Whiteside T.L. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004, 10:3755-3762.
86. Whiteside T.L. Immunobiology of head and neck cancer. Cancer Metast. Rev 2005, 24:95-105.
87. Dasgupta S., Bhattacharya-Chatterjee M., O'Malley B.W., Chatterjee S.K. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol 2005, 175:5541-5550.
88. Bauernhofer T., Kuss I., Henderson B., Baum A.S., Whiteside T.L. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol 2003, 33:119-124.
89. Ferris R., Whiteside T.L., Ferrone S. Clinical significance of downregulated antigen processing machinery in head and neck cancer. Clin Cancer Res 2006, 12:3890-3895.
90. Ceeraz S., Nowak E.C., Noelle R.J. B7 family checkpoint regulators in immuneregulation and disease. Trends Immunol 2013, 34:556-563.
91. Pedoeem A., Azoulay-Alfaguter I., Strazza M., Silverman G.J., Mor A. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol 2014, 153:145-152.
92. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677.
93. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
94. McDermott D.F., Atkins M.B. PD-1 as a potential target in cancer therapy. Cancer Med. 2013, 2:662.
95. Lyford-Pike S., Peng S., Young G.D., et al. Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Clin Cancer Res 2013, 73:1733-1741.
96. Badoual C., Hans S., Merillon N., et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013, 73(1):128-138.
97. Ghebeh H., Mohammed S., Al-Omair A., Qattan A., Lehe C., Al-Qudaihi G., et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high risk prognostic factors. Neoplasia 2006, 8(3):190-198.
98. Thompson R.H., Gillett M.D., Cheville J.C., et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 2005, 104(10):2084-2091.
99. Thompson R.H., Gillett M.D., Cheville J.C., et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004, 101:17174.
100. Tsushima F., Tanaka K., Otsuki N., et al. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol 2006, 42(3):268-274.
101. Cho Y.A., Yoon H.J., Lee J.I., et al. Relationship between the expressions of pd-l1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol 2011, 47:1148-1153.
102. Zandberg D.P., Bhargava R., Badin S., et al. The role of human papillomavirus in nongenital cancers. CA Cancer J Clin 2013, 63(1):57-81.
103. Posner M.R., Lorch J.H., Goloubeva O., et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011, 22(5):1071-1077.
104. Pentcheva-Hoang T., Simpson T.R., Montalvo-Ortiz W., Allison J.P. Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade enhances anti-tumor immunity by stimulating melanoma-specific T cell motility. Cancer Immunol Res Oct 2014, 2(10):970-980.
105. Vander Merwe P.A., Bodian D.L., Daenke S., et al. CD80(B7-1)binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997, 185:393-403.
106. Chen W.J., Jin W.W., Wahl S.M. Engagement of cytotoxic T lymphocyte- associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta)production by murine CD4(thorn) Tcells. J Exp Med 1998, 188:1849-1857.
107. Walunas T.L., Lenschow D.J., Bakker C.Y., et al. CTLA-4 can function as a negative regulator of T-cell activation. Immunity 1994, 1:405-413.
108. Linsley P.S., Brady W., Urnes M., et al. CTLA-4 is a 2nd receptor for the B-Cell activation antigen-B7. J Exp Med 1991, 174:561-569.
109. Peggs K.S., Quezada S.A., Chambers C.A., Korman A.J., Allison J.P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the anti-tumor activity of anti-CTLA-4 antibodies. J Exp Med 2009, 206:1717-1725.
110. Takahashi T., Tagami T., Yamazaki S., et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J ExpMed 2000, 192:303-310.
111. Read S., Malmstrom V., Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25 (+) CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000, 192(2):303-310. 17.
112. Kavanagh B., O'Brien S., Lee D., et al. CTLA-4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 2008, 112:1175-1183.
113. O'Mahony D., Morris J.C., Quinn C., et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007, 13:958-964.
114. Liakou C.I., Kamat A., Tang D.N., et al. CTLA-4 blockade increases IFN gamma-producing CD4+ ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 2008, 105:14987-14992.
115. Jie H.B., Schuler P.J., Lee S.C., et al. CTLA-4+ regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res 2015 Jun 1, 75(11):2200-2210.
116. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 Aug 19, 363(8):711-723.
117. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 30 Jun 2011, 364(26):2517-2526.
118. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369(12):33.
119. Seiwert T.Y., Burtness B., Weiss J., et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. J Clin Oncol 2014, 32(suppl. abstr 6011).
120. Chow L.Q., Burtness B., Weiss J., et al. A phase Ib study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with human papiilloma virus (HPV)-positive and negative head and neck cancer (HNC). Ann Oncol 2014, 25(5):1-41. 10.1093/annonc/mdu438.
121. Segal N.H., Ou S.H., Balmanoukian A.S., et al. Safety and efficacy of MEDI4736, an anti-PD-L1 antibody in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. J Clin Oncol 2015, 33(Suppl. abstr 3011):89-96.
122. Robert C., Schachter J., Long G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015, 372(26):2521-2532.
123. Larkin J., Chiarion-Sileni V., Gonzalez R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015, 373(1):23-34.
124. Schadendorf D., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015, 33:1889-1894.
125. Herbst R.S., Gordon M., Fine G., et al. A study of MPDL3280A, an engineered PDL1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol 2013, 31.
126. Hsu M.C., Hsiao J.R., Chang K.C., et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol 2010, 23(10):1393-1403.
127. Zandberg D.P., Strome S.E. The role of the PD-L1: PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 2014, 50:627-632.
128. Antonia S.J., Grosso J.F., Horak C.E., et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with non-small cell lung cancer (NSCLC) treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract]. J Thorac Oncol 2013, 8(Suppl. 2). abstr P2.11-035.
129. Garon E.B., Balmanoukian A., Hamid O., et al. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with NSCLC [abstract]. J Thorac Oncol 2013, 8(Suppl. 2). abstr MO18.02.
130. Brahmer J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366(26):2455-2465.
131. Malm I.J., Bruno T.C., Fu J., et al. Expression profile and in vitro blockade of PD-1 in HPV-negative head and neck squamous cell carcinoma. Head Neck 2015, 37(8):1088-1095.
132. Powderly J.D., Kluger H., Stephen, et al. Biomarkers and associations with clinical activity of PD-L1 blockade in a MPDL3280A study. J Clin Oncol 2013, 31.
133. Cho D., Sosman C., Sznol J.A., et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013, 31. (Suppl.) (abstract no. 4505).
134. Callea M. PD-L1 expression in primary clear cell renal cell carcinoma and their metastases. In: Presentation at Genitourinary Cancers Symposium. San Francisco, 2014; CA (abstract no. 467).
135. Wolchok J.D., Neyns B., Linette G., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomized, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010, 11(2):155-164.
136. Sznol M. Survival and long-term follow up of safety and response in patients with advanced melanoma in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 2014, 31. abstract CRA9006.
137. Parry R.V., Chemnitz J.M., Frauwirth K.A., et al. CTLA-4 and PD-1 receptors inhibit t-cell activation by distinct mechanisms. Mol Cell Biol 2005, 25:9543-9553.
138. Postow M.A., Chesney J., Pavlick A.C., et al. Nivolumab and ipilimumab versus ipilimumab in untreated mela- noma. N Engl J Med 2015, 372:2006-2017.
139. Goldberg M.V., Drake C.G. LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol 2011, 344:269-278.
140. Miyazaki T., Dierich A., Benoist C., et al. LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice. Int Immunol 1996, 8:725-729.
141. Sanchez-Fueyo A., Tian J., Picarella D., et al. TIM-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 2003, 4:1093-1101.
142. Sakuishi K., Jayaraman P., Behar S.M., et al. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol 2011, 32:345-349.
143. Sierro S., Romero P., Speiser D.E. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 2011, 15:91-101.
144. Triebel F., Jitsukawa S., Baixeras E., et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 1990, 171:1393-1405.
145. Baixeras E., Huard B., Miossec C., et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med 1992, 176:327-337.
146. Huang C.T., et al. Role of LAG-3 in regulatory T cells. Immunity 2004, 21:503-513.
147. Woo S.R., Turnis M.E., Goldberg M.V., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012, 72:917-927.
148. Wang-Gillam A., Plambeck-Suess S., Goedegebuure P., et al. A Phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 2013, 31(3):707-713.
149. Brignone C., Gutierrez M., Mefti F., et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3 Ig) enhances immune responses and antitumor activity. J Transl Med 2010 Jul, 23(8):71.
150. Brignone C., Escudier B., Grygar C., et al. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 2009, 15:6225-6231.
151. McIntire J.J., Umetsu S.E., Akbari O., et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol 2001, 2(12):1109-1116.
152. Freeman G.J., Casasnovas J.M., Umetsu D.T., et al. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 2010, 235:172-189.
153. Jin H.T., Anderson A.C., Tan W.G., et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA 2010, 107(33):14733-14738. 17.
154. Sakuishi K., Apetoh L., Sullivan J.M., et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010, 207(10):2187-2194.
155. Guo Z., Cheng D., Xia Z., et al. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med. 2013, 17(11):215.
156. Ngiow S.F., Teng M.W., Smyth M.J. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res 2011, 71:6567-6571.
157. Kehry M., Horlick R., Bowers P., et al. Targeting PD-1, TIM-3 and LAG-3 in combination for improved immunotherapy combinations. Cancer Res 2015, 75(Suppl. 15):271.
158. Woo S.R., Turnis M.E., Goldberg M.V., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T cell function to promote tumoral immune escape. Cancer Res 2012 February 15, 72(4):917-927.
159. Deng L., Liang H., Burnette B., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014, 124(2):687-695.
160. Zeng J., See A.P., Phallen J., et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013, 86(2):343-349.
161. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012, 12:237.
162. Matsumura S., Wang B., Kawashima N., et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector Tcells. J Immunol 2008, 181:3099-3107.
163. Lugade A.A., Moran J.P., Gerber S.A., et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005, 174:7516-7523.
164. Lugade A.A., Sorensen E.W., Gerber S.A., et al. Radiation-induced IFN- gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 2008, 180:3132-3139.
165. Grabenbauer G.G., Lahmer G., Distel L., et al. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 2006, 12(11):3355-3360.
166. Denkert C., Loibl S., Noske A., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010, 28(1):105-113.
167. Schaue D., Comin-Anduix B., Ribas A., et al. T-cell responses to surviving cancer patients undergoing radiation therapy. Clin Cancer Res 2008, 14(15):4883-4890.
168. Postow M.A., Callahan M.K., Barker C.A., et al. Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma. N Engl J Med 2012, 366:925-931.
169. Formenti S.C., Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009, 10:718-726.
170. Ruocco M.G., Pilones K.A., Kawashima N., et al. Suppressing Tcell motility induced by anti-CTLA-4 monotherapy improves anti-tumor effects. J Clin Invest 2012, 122:3718-3730.
171. Reits E.A., Hodge J.W., Herberts C.A., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006, 203:1259-1271.
172. Chakraborty M., Abrams S.I., Camphausen K., et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003, 170:6338-6347.
173. Kwilas A.R., Donahue R.N., Bernstein M.B., et al. Int he field: Exploiting the untapped potentiallo fimmunogenic modulation byradiation in combination with immunotherapy for the treatment of cancer. Front Oncol 2012, 2:104.
174. Parikh F., Duluc D., Imai N., et al. Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. Cancer Res 2014, 74(24):7205-7216.
175. Moyer J.S., Maine G., Mule J.J. Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects. Biol Blood Marrow Transpl 2006, 12:1010-1019.
176. Teitz-Tennenbaum S., Li Q., Rynkiewicz S., et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 2003, 63:8466-8475.
177. Teitz-Tennenbaum S., Li Q., Okuyama R., et al. Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J Immunother 2008, 31:345-358.
178. Dewan M.Z., Galloway A.E., Kawashima N., et al. Fractionated but not single dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15:5379-5388.
179. Stamell E.F., Wolchok J.D., Gnjatic S., et al. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 2013, 85:293-295.
180. Hiniker S.M., Chen D.S., Reddy S., et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 2012, 5:404-407.
181. Golden E.B., Demaria S., Schiff P.B., et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013, 1:365-372.
182. Strauss L., Bergmann C., Gooding W., Johnson J.T., Whiteside T.L. The frequency and suppressor function of CD4+ CD25high Foxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007, 13:6301-6311.
183. Jie H.B., Gildener-Leapman N., Li J., et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 2013, 109:2629-2635.
184. Begg A.C. Predicting recurrence after radiotherapy in head and neck cancer. Semin Radiat Oncol 2012 Apr, 22(2):108-118.
185. Apetoh L., Ghiringhelli F., Tesniere A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059.
186. Bhardwaj N. Harnessing the immune system to treat cancer. J Clin Invest 2007, 117:1130-1136.
187. Burnette B., Weichselbaum R.R. Radiation as an immune modulator. Semin Radiat Oncol 2013, 23:273-280.
188. Balermpas P., Michel Y., Wangenblast J., et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer 2014, 110(2):501-509.
189. Schlom J., Hodge J.W., Palena C., et al. Therapeutic cancer vaccines. Adv Cancer Res 2014, 121:67-124.
190. Schuler P.J., Harasymczuk M., Visus C., et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 2014, 20:2433-2444.
191. Voskens C.J., Sewell D., Hertzano R., et al. Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck 2012, 34:1734-1746.
192. Brun J.L., Dalstein V., Leveque J., et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 2011, 204(169):e1-8.
193. Kenter G.G., Welters M.J., Valentijn A.R., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847.
194. Yoshitake Y., Fukuma D., Yuno A., et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of Immune responses and improved OS. Clin Cancer Res 2014, 21(2):1-10.
195. Barrera J.L., Verastegui E., Meneses A., et al. Combination immunotherapy of squamous cell carcinoma of the head and neck. A phase 2 trial. Arch Otolaryngol Head Neck Surg 2000, 126:345-351.
196. Bartlett D.L., Liu Z., Sathaiah M., et al. Oncolytic viruses as therapeutic cancer vaccines. Molecular Cancer 2013, 12:103.